<DOC>
	<DOCNO>NCT00005934</DOCNO>
	<brief_summary>This study evaluate safety effectiveness 5-azacytidine phenylbutyrate treat thalassemia major . Patients disease abnormal production hemoglobin ( oxygen-carrying protein red blood cell ) , lead red blood cell destruction . As result , patient require frequent red cell transfusion many year . Because transfusion , however , excess iron deposit various body organs-such heart , liver , thyroid gland , men , testes-impairing function . Fetal hemoglobin-a type hemoglobin produce fetal infant life-can substitute adult hemoglobin increase level red cell body . After infancy , however , type hemoglobin longer produce large quantity . 5-azacytidine increase fetal hemoglobin level , drug damage DNA , turn increase risk cancer . This study try lessen harmful effect 5-azacytidine use one two dos , follow long-term therapy phenylbutyrate , drug may effective 5-azacytidine less harmful side effect . Patients 18 year age old severe thalassemia major may eligible study . Before begin treatment , candidate medical history physical examination , blood test , chest X-ray , electrocardiogram ( EKG ) , bone marrow biopsy ( removal small sample bone marrow hip microscopic examination ) whole-body magnetic resonance imaging ( MRI ) . For biopsy , area hip anesthetize special needle insert draw bone marrow hipbone . For MRI scan , strong magnetic field use produce image identify site body make red blood cell . During procedure , patient lie table narrow cylinder contain magnetic field . Earplugs place ear muffle loud thump sounds machine make magnetic field switch . An intravenous ( IV ) catheter ( flexible tube insert vein ) place large vein patient 's neck , chest arm infusion 5-azacytidine constant rate 4 day . Patients respond first dose 5-azacytidine give drug 50 day . If respond second dose , alternate treatment consider . Patients respond 5-azacytidine begin take phenylbutyrate 14th day 5-azacytidine start . They take 10 large pill 3 time day , continue long treatment beneficial . All patient hospitalize least 6 day start begin 5-azacytidine therapy . Those well enough may discharge continue treatment outpatient . Patients monitor blood test daily 2 week see weekly another 5 week . Bone marrow biopsy repeat 6 day treatment begin 2 week 7 week . MRI repeat 7 week treatment begin . After 7 week , patient see 3-month interval . Bone marrow biopsy do every 6 month first 3 year treatment . Patients red cell transfusion need chelation therapy remove excess iron .</brief_summary>
	<brief_title>5-Azacytidine Phenylbutyrate Treat Severe Thalassemia</brief_title>
	<detailed_description>Individuals homozygous beta-thalassemia either severely anemic dependent blood transfusion sustain life . Deficient synthesis beta chain lead imbalanced chain synthesis excess alpha globin . This alpha globin precipitate , cause ineffective erythropoiesis shorten red cell survival . In patient homozygous beta-thalassemia , enhanced gamma globin synthesis could partially compensate deficient synthesis beta globin render chain synthesis balance reduce relative excess alpha chain . The purpose protocol test hypothesis induction therapy 5-azacytidine , follow maintenance treatment oral phenylbutyrate enhance gamma globin synthesis , increase red cell production partially substantially correct anemia patient homozygous beta-thalassemia .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>4-phenylbutyric acid</mesh_term>
	<criteria>INCLUSION CRITERIA : Thalassemia major progressive disease complication iron overload despite traditional transfusion iron chelation therapy Thalassemia major standard transfusion therapy iron chelation therapy contraindicate ECOG performance status must less equal 2 NYHA less equal class II status Progressive disease define 1 ) increase transfusion requirement difficulty maintenance hemoglobin level great 7g/dl consequence autologous allogeneic antibody 2 ) increase extramedullary hematopoiesis cause compression phenomenon . Complications iron overload despite iron chelation therapy define difficulty achieve negative iron balance complication iron overload exist . Complications iron overload include heart failure , decrease cardiac ejection fraction , endocrinopathy evidence progressive liver dysfunction . EXCLUSION CRITERIA : Severe sepsis septic shock Current pregnancy breast feed Not able give inform consent Altered mental status seizure disorder AST ALT great 3X upper limit normal Bilirubin great than1.5X upper limit normal , unless abnormal bilirubin account indirect hyperbilirubinemia due hemolysis Gilbert 's Disease Serum albumin less 3g/dl Creatinine great 2mg/dl creatinine clearance le 60ml/min Patients moribund patient concurrent hepatic , renal , cardiac , metabolic , disease severity death within 710 day likely Concurrent myelodysplastic syndrome leukemia NYHA class III/IV status ECOG performance status great 2 Age less 18 year</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2003</verification_date>
	<keyword>Fetal Hemoglobin</keyword>
	<keyword>5-Azacytidine</keyword>
	<keyword>Phenylbutyrate</keyword>
	<keyword>Thalassemia</keyword>
	<keyword>Hemoglobin</keyword>
	<keyword>Anemia</keyword>
	<keyword>Blood</keyword>
	<keyword>Thalassemia Major</keyword>
	<keyword>Beta Thalassemia</keyword>
</DOC>